IC/ES数据库中前沿自由式Libre系统在安大略省糖尿病患者中的应用——来自现实世界实践的证据:患者使用强化胰岛素

IF 5.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Alexandria Ratzki-Leewing, Stewart B Harris, Rémi Rabasa-Lhoret, Yeesha Poon
{"title":"IC/ES数据库中前沿自由式Libre系统在安大略省糖尿病患者中的应用——来自现实世界实践的证据:患者使用强化胰岛素","authors":"Alexandria Ratzki-Leewing, Stewart B Harris, Rémi Rabasa-Lhoret, Yeesha Poon","doi":"10.1089/dia.2024.0609","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background:</i></b> Diabetes mellitus is associated with significant health care resource utilization (HCRU), partly due to acute complications, including diabetic ketoacidosis (DKA) and hypoglycemia. <b><i>Aim:</i></b> To investigate glycated hemoglobin (HbA1c) levels and HCRU before and after adoption of FreeStyle Libre Systems (FSL) in people with diabetes on multiple daily injections of insulin (MDI). <b><i>Methods:</i></b> This retrospective longitudinal study used administrative health data in Ontario, Canada, housed at IC/ES. The cohort comprised people with diabetes on MDI with a first FSL claim between September 16, 2019, and August 31, 2020 (index date), who remained on FSL for 24 months. HCRU (emergency department [ED] visits and hospitalization) was measured for 12 months before the index date and the last 12 months of follow-up. HbA1c data were taken from the last tests in each period. <b><i>Results:</i></b> Mean HbA1c was statistically significantly reduced after FSL among people with type 1 diabetes mellitus (T1DM; <i>n</i> = 10,510; age <25 years, -0.8%; 25-65 years, -0.5%; >65 years, -0.1%; all <i>P</i> < 0.0001) or type 2 diabetes mellitus (T2DM; <i>n</i> = 12,668; age ≤65 years, -0.6%; >65 years, -0.3%; both <i>P</i> < 0.0001). Overall HCRU was statistically significantly reduced in the T1DM subgroups aged <25 and 25-65 years (ED visits only) and both T2DM age subgroups, with some subgroups having statistically significant reductions in DKA- or hypoglycemia-associated HCRU. <b><i>Conclusions:</i></b> Among people with T1DM or T2DM on MDI, HbA1c was statistically significantly reduced after FSL, with statistically significant reductions in HCRU in some subgroups.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"FRONTIER-FreeStyle Libre System Use in Ontario Among People with Diabetes Mellitus in the IC/ES Database-Evidence from Real-World Practice: Patients Using Intensive Insulin.\",\"authors\":\"Alexandria Ratzki-Leewing, Stewart B Harris, Rémi Rabasa-Lhoret, Yeesha Poon\",\"doi\":\"10.1089/dia.2024.0609\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Background:</i></b> Diabetes mellitus is associated with significant health care resource utilization (HCRU), partly due to acute complications, including diabetic ketoacidosis (DKA) and hypoglycemia. <b><i>Aim:</i></b> To investigate glycated hemoglobin (HbA1c) levels and HCRU before and after adoption of FreeStyle Libre Systems (FSL) in people with diabetes on multiple daily injections of insulin (MDI). <b><i>Methods:</i></b> This retrospective longitudinal study used administrative health data in Ontario, Canada, housed at IC/ES. The cohort comprised people with diabetes on MDI with a first FSL claim between September 16, 2019, and August 31, 2020 (index date), who remained on FSL for 24 months. HCRU (emergency department [ED] visits and hospitalization) was measured for 12 months before the index date and the last 12 months of follow-up. HbA1c data were taken from the last tests in each period. <b><i>Results:</i></b> Mean HbA1c was statistically significantly reduced after FSL among people with type 1 diabetes mellitus (T1DM; <i>n</i> = 10,510; age <25 years, -0.8%; 25-65 years, -0.5%; >65 years, -0.1%; all <i>P</i> < 0.0001) or type 2 diabetes mellitus (T2DM; <i>n</i> = 12,668; age ≤65 years, -0.6%; >65 years, -0.3%; both <i>P</i> < 0.0001). Overall HCRU was statistically significantly reduced in the T1DM subgroups aged <25 and 25-65 years (ED visits only) and both T2DM age subgroups, with some subgroups having statistically significant reductions in DKA- or hypoglycemia-associated HCRU. <b><i>Conclusions:</i></b> Among people with T1DM or T2DM on MDI, HbA1c was statistically significantly reduced after FSL, with statistically significant reductions in HCRU in some subgroups.</p>\",\"PeriodicalId\":11159,\"journal\":{\"name\":\"Diabetes technology & therapeutics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2025-02-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes technology & therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1089/dia.2024.0609\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/dia.2024.0609","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景:糖尿病与显著的卫生保健资源利用(HCRU)相关,部分原因是急性并发症,包括糖尿病酮症酸中毒(DKA)和低血糖。目的:探讨每日多次注射胰岛素(MDI)的糖尿病患者采用FreeStyle Libre系统(FSL)前后的糖化血红蛋白(HbA1c)水平和HCRU。方法:本回顾性纵向研究使用了加拿大安大略省IC/ES的行政卫生数据。该队列包括在2019年9月16日至2020年8月31日(索引日期)期间接受MDI治疗的首次FSL索赔的糖尿病患者,他们持续服用FSL 24个月。HCRU(急诊科[ED]就诊和住院)测量在索引日期前12个月和最后12个月的随访。HbA1c数据取自每个周期的最后一次检测。结果:1型糖尿病患者(T1DM;N = 10,510;65岁,-0.1%;P < 0.0001)或2型糖尿病(T2DM;N = 12,668;年龄≤65岁,-0.6%;65年,-0.3%;P < 0.0001)。结论:在患有T1DM或T2DM的MDI患者中,FSL后HbA1c有统计学意义上的降低,在某些亚组中HCRU有统计学意义上的降低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
FRONTIER-FreeStyle Libre System Use in Ontario Among People with Diabetes Mellitus in the IC/ES Database-Evidence from Real-World Practice: Patients Using Intensive Insulin.

Background: Diabetes mellitus is associated with significant health care resource utilization (HCRU), partly due to acute complications, including diabetic ketoacidosis (DKA) and hypoglycemia. Aim: To investigate glycated hemoglobin (HbA1c) levels and HCRU before and after adoption of FreeStyle Libre Systems (FSL) in people with diabetes on multiple daily injections of insulin (MDI). Methods: This retrospective longitudinal study used administrative health data in Ontario, Canada, housed at IC/ES. The cohort comprised people with diabetes on MDI with a first FSL claim between September 16, 2019, and August 31, 2020 (index date), who remained on FSL for 24 months. HCRU (emergency department [ED] visits and hospitalization) was measured for 12 months before the index date and the last 12 months of follow-up. HbA1c data were taken from the last tests in each period. Results: Mean HbA1c was statistically significantly reduced after FSL among people with type 1 diabetes mellitus (T1DM; n = 10,510; age <25 years, -0.8%; 25-65 years, -0.5%; >65 years, -0.1%; all P < 0.0001) or type 2 diabetes mellitus (T2DM; n = 12,668; age ≤65 years, -0.6%; >65 years, -0.3%; both P < 0.0001). Overall HCRU was statistically significantly reduced in the T1DM subgroups aged <25 and 25-65 years (ED visits only) and both T2DM age subgroups, with some subgroups having statistically significant reductions in DKA- or hypoglycemia-associated HCRU. Conclusions: Among people with T1DM or T2DM on MDI, HbA1c was statistically significantly reduced after FSL, with statistically significant reductions in HCRU in some subgroups.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信